Second Sight Medical Products (Second Sight Medical Products) ROCE % : -19.37% (As of Jun. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Second Sight Medical Products ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Second Sight Medical Products's annualized ROCE % for the quarter that ended in Jun. 2022 was -19.37%.

Second Sight Medical Products ROCE % Historical Data

The historical data trend for Second Sight Medical Products's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Second Sight Medical Products ROCE % Chart

Second Sight Medical Products Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

ROCE %

Get a 7-Day Free Trial

-300.67

-631.50

-480.93

-282.49

-26.37

Second Sight Medical Products Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
ROCE %	Get a 7-Day Free Trial															-19.65	-14.10	-7.48	-13.17	-19.37

Second Sight Medical Products ROCE % Calculation

Second Sight Medical Products's annualized ROCE % for the fiscal year that ended in Dec. 2021 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	-8.933	/	( ( (4.46 - 5.132)	+	(70.879 - 2.462) )	/ 2 )
	=	-8.933	/	( (-0.672	+	68.417)	/ 2 )
	=	-8.933	/	33.8725
	=	-26.37 %

Second Sight Medical Products's ROCE % of for the quarter that ended in Jun. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2022 )		(Q: Mar. 2022 )		(Q: Jun. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2022 )		(Q: Mar. 2022 )		(Q: Jun. 2022 )
	=	-12.516	/	( ( (68.538 - 2.385)	+	(65.649 - 2.591) )	/ 2 )
	=	-12.516	/	( ( 66.153	+	63.058 )	/ 2 )
	=	-12.516	/	64.6055
	=	-19.37 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2022) EBIT data.

Second Sight Medical Products (NAS:EYESW) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Second Sight Medical Products ROCE % Related Terms

Thank you for viewing the detailed overview of Second Sight Medical Products's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Second Sight Medical Products (Second Sight Medical Products) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Second Sight Medical Products Inc (NAS:EYESW) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

13170 Telfair Avenue, Sylmar, CA, USA, 91342

Website

https://www.secondsight.com

Second Sight Medical Products Inc develops, manufactures, and markets implantable prosthetic devices to create an artificial form of useful vision for blind individuals. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. Geographically, the company operates in the United States, Italy, China, and of which key revenue is derived from the United States.